Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain
Status:
Suspended
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Aim of this project is to customize the choice of the strong opioid in the treatment of
cancer chronic pain through the identification of patient clinical history and pain
characteristics, moreover in the analysis the investigators will also correlate the clinical
efficacy and safety of opioid treatment with pharmacokinetic and pharmacogenetic patterns in
order to identify variables able to predict the efficacy of the treatment or the patient
susceptibility towards a specific treatment.
Furthermore with this study the investigators want to identify the pharmacogenomic
characterization responsible for pharmacokinetic variability in the conversion between
morphine and other opioids, in order to validate the currently available conversion tables
from a pharmacokinetic viewpoint, estimating the influence of the most common genetic
polymorphisms, and if this characterization could be useful and cost-effective. This study
will also focus on the specific clinical-pharmacological response in the elderly and between
male and female and on the interactions between opioids and those anticonvulsant and
antidepressant drugs routinely used in the pain therapy (study of pharmacovigilance).